Literature DB >> 19345327

Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors.

Heehyoung Lee1, Andreas Herrmann, Jie-Hui Deng, Maciej Kujawski, Guilian Niu, Zhiwei Li, Steve Forman, Richard Jove, Drew M Pardoll, Hua Yu.   

Abstract

NF-kappaB (RelA) is constitutively active in many cancers, where it upregulates antiapoptotic and other oncogenic genes. While proinflammatory stimulus-induced NF-kappaB activation involves IKK-dependent nuclear translocation, mechanisms for maintaining constitutive NF-kappaB activity in tumors have not been elucidated. We show here that maintenance of NF-kappaB activity in tumors requires Stat3, which is also frequently constitutively activated in cancer. Stat3 prolongs NF-kappaB nuclear retention through acetyltransferase p300-mediated RelA acetylation, thereby interfering with NF-kappaB nuclear export. Stat3-mediated maintenance of NF-kappaB activity occurs in both cancer cells and tumor-associated hematopoietic cells. Both murine and human cancers display highly acetylated RelA, which is associated with Stat3 activity. This Stat3/NF-kappaB interaction is thus central to both the transformed and nontransformed elements in tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19345327      PMCID: PMC2777654          DOI: 10.1016/j.ccr.2009.02.015

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  45 in total

1.  A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes.

Authors:  T T Huang; N Kudo; M Yoshida; S Miyamoto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

2.  CARD11 mediates factor-specific activation of NF-kappaB by the T cell receptor complex.

Authors:  Joel L Pomerantz; Elissa M Denny; David Baltimore
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

Review 3.  Transcription factors as targets for cancer therapy.

Authors:  James E Darnell
Journal:  Nat Rev Cancer       Date:  2002-10       Impact factor: 60.716

4.  Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL-6 stimulation.

Authors:  J J Schuringa; H Schepers; E Vellenga; W Kruijer
Journal:  FEBS Lett       Date:  2001-04-20       Impact factor: 4.124

Review 5.  NF-kappaB in cancer: from innocent bystander to major culprit.

Authors:  Michael Karin; Yixue Cao; Florian R Greten; Zhi-Wei Li
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

6.  Duration of nuclear NF-kappaB action regulated by reversible acetylation.

Authors:  W Fischle; E Verdin; W C Greene
Journal:  Science       Date:  2001-08-31       Impact factor: 47.728

7.  Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells. Evidence for a dual kinase mechanism.

Authors:  Dayanand D Deo; T William Axelrad; Everett G Robert; Victor Marcheselli; Nicolas G Bazan; Jay D Hunt
Journal:  J Biol Chem       Date:  2002-04-08       Impact factor: 5.157

8.  Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a.

Authors:  Sandrine Giraud; Frédéric Bienvenu; Sylvie Avril; Hugues Gascan; David M Heery; Olivier Coqueret
Journal:  J Biol Chem       Date:  2001-12-31       Impact factor: 5.157

9.  Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment.

Authors:  Marcin Kortylewski; Hong Xin; Maciej Kujawski; Heehyoung Lee; Yong Liu; Timothy Harris; Charles Drake; Drew Pardoll; Hua Yu
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

10.  STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation.

Authors:  Chien-kuo Lee; Regina Raz; Ramon Gimeno; Rachel Gertner; Birte Wistinghausen; Kenichi Takeshita; Ronald A DePinho; David E Levy
Journal:  Immunity       Date:  2002-07       Impact factor: 31.745

View more
  297 in total

1.  JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.

Authors:  Andrea Bonetto; Tufan Aydogdu; Xiaoling Jin; Zongxiu Zhang; Rui Zhan; Leopold Puzis; Leonidas G Koniaris; Teresa A Zimmers
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-06-05       Impact factor: 4.310

2.  Conditional ablation of Ikkb inhibits melanoma tumor development in mice.

Authors:  Jinming Yang; Ryan Splittgerber; Fiona E Yull; Sara Kantrow; Gregory D Ayers; Michael Karin; Ann Richmond
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

3.  Breaking the NF-κB and STAT3 alliance inhibits inflammation and pancreatic tumorigenesis.

Authors:  Young-Joon Surh; Ann M Bode; Zigang Dong
Journal:  Cancer Prev Res (Phila)       Date:  2010-10-26

Review 4.  Translational approaches to treatment-induced symptoms in cancer patients.

Authors:  Robert Dantzer; Mary W Meagher; Charles S Cleeland
Journal:  Nat Rev Clin Oncol       Date:  2012-05-29       Impact factor: 66.675

5.  Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway.

Authors:  Guanglei Zhuang; Xiumin Wu; Zhaoshi Jiang; Ian Kasman; Jenny Yao; Yinghui Guan; Jason Oeh; Zora Modrusan; Carlos Bais; Deepak Sampath; Napoleone Ferrara
Journal:  EMBO J       Date:  2012-07-06       Impact factor: 11.598

6.  Lipopolysaccharide enhances mouse lung tumorigenesis: a model for inflammation-driven lung cancer.

Authors:  T Melkamu; X Qian; P Upadhyaya; M G O'Sullivan; F Kassie
Journal:  Vet Pathol       Date:  2013-02-04       Impact factor: 2.221

7.  Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.

Authors:  Chi Young Ok; Ling Li; Zijun Y Xu-Monette; Carlo Visco; Alexander Tzankov; Ganiraju C Manyam; Santiago Montes-Moreno; Karen Dybkaer; Karen Dybaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Jiayu Chen; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; John P Farnen; Michael B Møller; Carlo E Bueso-Ramos; Roberto N Miranda; Jane N Winter; Miguel A Piris; L Jeffrey Medeiros; Ken H Young
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

8.  T cell receptor/CARMA1/NF-κB signaling controls T-helper (Th) 17 differentiation.

Authors:  Luciana L Molinero; Alan Cubre; Carolina Mora-Solano; Ying Wang; Maria-Luisa Alegre
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-22       Impact factor: 11.205

9.  IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L.

Authors:  Ilona Kryczek; Yanwei Lin; Nisha Nagarsheth; Dongjun Peng; Lili Zhao; Ende Zhao; Linda Vatan; Wojciech Szeliga; Yali Dou; Scott Owens; Witold Zgodzinski; Marek Majewski; Grzegorz Wallner; Jingyuan Fang; Emina Huang; Weiping Zou
Journal:  Immunity       Date:  2014-05-08       Impact factor: 31.745

10.  miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells.

Authors:  Nicola Amodio; Dina Bellizzi; Marzia Leotta; Lavinia Raimondi; Lavinia Biamonte; Patrizia D'Aquila; Maria Teresa Di Martino; Teresa Calimeri; Marco Rossi; Marta Lionetti; Emanuela Leone; Giuseppe Passarino; Antonino Neri; Antonio Giordano; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Cell Cycle       Date:  2013-09-25       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.